SBI Biotech is a bio-venture founded under proposal by Dr. Kenichi Arai (a leading molecular biologist and immunologist and now President of the company), Dr. Jacques Banchereau (Director of the Baylor Institute for Immunology Research, U.S.), and Dr. Yong Jun Liu (Director of the Center for Cancer Immunology Research, M. D. Anderson Cancer Center, U.S.) and with approval from SBI Holdings. Combining antibody, nucleic acid, and low-molecular drugs with cell remedies, we strive for contribution to new immunotherapy and cancer treatment.
With the progress of life science, medical science, and information technology, we are now in the age of personalized medical care. Cutting-edge treatments, disease prevention, longevity, and healthy living are left to our own choice. Through independent and third-party research and product development, we work hard to help achieve what conventional drug discovery ventures and pharmaceutical companies have not done, including the establishment of a genome and cell remedy platform, creation of a communication structure open to drug-discovery organizations, clinics, and patients, and generation of a new medical and healthcare service industry.
Due to the difficulty in securing subsequent drug seeds, few Japanese drug-discovery ventures sustain growth after successfully developing one medicine. However, with efforts to solve this problem by working together with world research leaders and aligning with major research institutions, bio-ventures, and pharmaceutical companies around the world, we strive for significant growth in the fields of basic research for drug development and marketing of pharmaceutical products as a Japanese-U.S.-Chinese-Korean drug-discovery joint bio-venture.
